J Korean Med Sci.  2017 Oct;32(10):1662-1668. 10.3346/jkms.2017.32.10.1662.

Oncologic Outcomes and Predictive Factors for Recurrence Following Robot-Assisted Radical Cystectomy for Urothelial Carcinoma: Multicenter Study from Korea

• Shim JS
• Kwon TG
• Rha KH
• Lee YG
• Lee JY
• Jeong BC
• Kim JY
• Pyun JH
• Kang SG
• Kang SH

• KMID: 2400439
• DOI: http://doi.org/10.3346/jkms.2017.32.10.1662

Abstract

The aim of our study was to evaluate intermediate-term oncologic outcomes, predictive factors for recurrence, and recurrence patterns in a multicenter series of patients treated with robot-assisted radical cystectomy (RARC) for urothelial carcinoma (UC) of the bladder. Between 2007 and 2015, 346 patients underwent RARC at multiple tertiary referral centers in Korea. Descriptive statistics were used for demographics and perioperative variables. Survival and recurrence were estimated with Kaplan-Meier analysis. Logistic regression models were used to determine predictors of recurrence. Median follow-up was 33 months (interquartile range [IQR], 7-50). The numbers of patients with organ-confined and lymph node (LN)-positive disease were 237 (68.4%) and 68 (19.7%), respectively. LN density (1-20 vs. > 20) was 13.6% and 6.1%, with a median of 17 nodes removed (IQR, 9-23). In logistic regression analysis, type of LN dissection, and pathologic tumor stage were significant predictors of cancer recurrence and death from cancer. Local, distal recurrence and secondary UC occurred in 7 (2.0%), 53 (15.3%), and 4 (1.2%) patients, respectively. The 5-year overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were 78%, 84%, and 73%, respectively. At last follow-up, RFS for extended pelvic LN dissection vs. standard pelvic LN dissection was 70% and 47% (P = 0.038). In addition, at last follow-up, LN density (0 vs. 1-20 vs. over 20) was 67%, 41%, and 29%, respectively (P < 0.001). Patients undergoing RARC in this multi-institutional cohort demonstrated intermediate-term oncologic outcomes, predictive factors for recurrence, and recurrence patterns that were not unusual.

Keyword

Bladder Cancer; Outcomes; Recurrence; Radical Cystectomy; Urothelial Carcinoma

MeSH Terms

Cohort Studies
Cystectomy*
Demography
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Korea*
Logistic Models
Lymph Nodes
Recurrence*
Tertiary Care Centers
Urinary Bladder
Urinary Bladder Neoplasms

Figure

• 

  Fig. 1 Distribution of locations among patients with recurrence after RARC. RARC = robot-assisted radical cystectomy, PLND = pelvic lymph node dissection.

• 

  Fig. 2 Kaplan-Meier curves for: OS of 93%, 84%, and 78% for 1-, 3-, and 5-year, respectively; CSS of 94%, 87%, and 84% for 1-, 3-, and 5-years, respectively; RFS of 88%, 78%, and 73% for 1-, 3-, and 5-years, respectively. OS = overall survival, CSS = cancer-specific survival, RFS = recurrence-free survival.

• 

  Fig. 3 Kaplan-Meier curves for oncologic outcome. (A) RFS at last follow-up for organ-confined vs. non-organ-confined disease was 68% vs. 51%, respectively (P < 0.001); (B) RFS at last follow-up for extended and standard PLND was 70% vs. 47%, respectively (P = 0.038); (C) RFS at last follow-up between LN density was 67%, 41%, and 29%, respectively (P < 0.001); and (D) RFS at last follow-up for negative vs. positive soft tissue margin status was 64% vs. not calculable, respectively (P < 0.001). RFS = recurrence-free survival, PLND = pelvic lymph node dissection, LN = lymph node.

Reference

1. Herr HW. Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer. Eur Urol. 2009; 55:303–305.

2. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006; 176:2414–2422.

3. Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol. 2010; 57:196–201.

4. Challacombe BJ, Bochner BH, Dasgupta P, Gill I, Guru K, Herr H, Mottrie A, Pruthi R, Redorta JP, Wiklund P. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol. 2011; 60:767–775.

5. Styn NR, Montgomery JS, Wood DP, Hafez KS, Lee CT, Tallman C, He C, Crossley H, Hollenbeck BK, Weizer AZ. Matched comparison of robotic-assisted and open radical cystectomy. Urology. 2012; 79:1303–1308.

6. Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, Coleman JA, Mathew S, Vickers A, Schnorr GC, et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol. 2015; 67:1042–1050.

7. Raza SJ, Wilson T, Peabody JO, Wiklund P, Scherr DS, Al-Daghmin A, Dibaj S, Khan MS, Dasgupta P, Mottrie A, et al. Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2015; 68:721–728.

8. Khan MS, Elhage O, Challacombe B, Murphy D, Coker B, Rimington P, O'Brien T, Dasgupta P. Long-term outcomes of robot-assisted radical cystectomy for bladder cancer. Eur Urol. 2013; 64:219–224.

9. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, Shariat SF, Scherr DS. Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. Urology. 2013; 82:1323–1329.

10. van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011; 60:493–500.

11. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001; 166:1296–1299.

12. Collins JW, Tyritzis S, Nyberg T, Schumacher M, Laurin O, Khazaeli D, Adding C, Jonsson MN, Hosseini A, Wiklund NP. Robot-assisted radical cystectomy: description of an evolved approach to radical cystectomy. Eur Urol. 2013; 64:654–663.

13. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005; 13:143–153.

14. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003; 170:35–41.

15. Thalmann GN, Stein JP. Outcomes of radical cystectomy. BJU Int. 2008; 102:1279–1288.

16. Yuh B, Wilson T, Bochner B, Chan K, Palou J, Stenzl A, Montorsi F, Thalmann G, Guru K, Catto JW, et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. Eur Urol. 2015; 67:402–422.

17. Wiesner C, Salzer A, Thomas C, Gellermann-Schultes C, Gillitzer R, Hampel C, Thüroff JW. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density. BJU Int. 2009; 104:331–335.

18. Leissner J, Ghoneim MA, Abol-Enein H, Thüroff JW, Franzaring L, Fisch M, Schulze H, Managadze G, Allhoff EP, el-Baz MA, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004; 171:139–144.

19. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002; 167:1295–1298.

20. Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003; 170:1765–1771.

21. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol. 2003; 169:943–945.

22. Ku JH, Kang M, Kim HS, Jeong CW, Kwak C, Kim HH. Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer. 2015; 15:447.

23. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010; 183:2165–2170.

24. Al-Daghmin A, English S, Kauffman EC, Din R, Khan A, Syed JR, Sztorc J, Mehedint D, Sharif M, Shi Y, et al. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2014; 114:253–260.

25. Nguyen DP, Al Hussein Al Awamlh B, Wu X, O'Malley P, Inoyatov IM, Ayangbesan A, Faltas BM, Christos PJ, Scherr DS. Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. Eur Urol. 2015; 68:399–405.

26. Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, et al. Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int. 2012; 110:1317–1323.

27. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64:639–653.

28. Snow-Lisy DC, Campbell SC, Gill IS, Hernandez AV, Fergany A, Kaouk J, Haber GP. Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes. Eur Urol. 2014; 65:193–200.

29. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19:666–675.

30. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21:690–696.